Despite improvements in chemotherapy leading to cures in most patients with MGTD, very little progress has been made toward long-term survival in those patients who progress on initial sequential single-agent or combination chemotherapy. This has led to a search for new active drugs and effective drug combinations for use as initial treatment in high-risk patients and as second-line agents in those for whom primary chemotherapy failed.
|Original language||English (US)|
|Number of pages||4|
|Journal||New York State Journal of Medicine|
|State||Published - Jan 1 1980|
ASJC Scopus subject areas